PMID- 31324219
OWN - NLM
STAT- MEDLINE
DCOM- 20200116
LR  - 20211204
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Jul 19
TI  - Use of precision cut lung slices as a translational model for the study of lung 
      biology.
PG  - 162
LID - 10.1186/s12931-019-1131-x [doi]
LID - 162
AB  - Animal models remain invaluable for study of respiratory diseases, however, 
      translation of data generated in genetically homogeneous animals housed in a 
      clean and well-controlled environment does not necessarily provide insight to the 
      human disease situation. In vitro human systems such as air liquid interface 
      (ALI) cultures and organ-on-a-chip models have attempted to bridge the divide 
      between animal models and human patients. However, although 3D in nature, these 
      models struggle to recreate the architecture and complex cellularity of the 
      airways and parenchyma, and therefore cannot mimic the complex cell-cell 
      interactions in the lung. To address this issue, lung slices have emerged as a 
      useful ex vivo tool for studying the respiratory responses to inflammatory 
      stimuli, infection, and novel drug compounds. This review covers the practicality 
      of precision cut lung slice (PCLS) generation and benefits of this ex vivo 
      culture system in modeling human lung biology and disease pathogenesis.
FAU - Liu, Guanghui
AU  - Liu G
AD  - RIA Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, 
      AstraZeneca, Gothenburg, Sweden.
FAU - Betts, Catherine
AU  - Betts C
AD  - Pathology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, 
      AstraZeneca, Cambridge, UK.
FAU - Cunoosamy, Danen M
AU  - Cunoosamy DM
AD  - Bioscience, Respiratory Inflammation and Autoimmunity, BioPharmaceuticals R&D, 
      AstraZeneca, Gothenburg, Sweden.
AD  - Present Address: Sanofi, Cambridge, MA, USA.
FAU - Aberg, Per M
AU  - Aberg PM
AD  - RIA Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, 
      AstraZeneca, Gothenburg, Sweden.
FAU - Hornberg, Jorrit J
AU  - Hornberg JJ
AD  - RIA Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, 
      AstraZeneca, Gothenburg, Sweden.
FAU - Sivars, Kinga Balogh
AU  - Sivars KB
AD  - RIA Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, 
      AstraZeneca, Gothenburg, Sweden.
FAU - Cohen, Taylor S
AU  - Cohen TS
AUID- ORCID: 0000-0001-9368-0903
AD  - Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, 
      Gaithersburg, MD, 20877, USA. cohent@medimmune.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190719
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
SB  - IM
MH  - Animals
MH  - Asthma/*pathology/physiopathology
MH  - Humans
MH  - Lung/*pathology/*physiology
MH  - Organ Culture Techniques/methods
MH  - Translational Research, Biomedical/*methods
PMC - PMC6642541
OTO - NOTNLM
OT  - Precision cut lung slices
OT  - Respiratory biology
OT  - Translational model
COIS- All authors are employees of AstraZeneca.
EDAT- 2019/07/22 06:00
MHDA- 2020/01/17 06:00
PMCR- 2019/07/19
CRDT- 2019/07/21 06:00
PHST- 2019/02/15 00:00 [received]
PHST- 2019/07/09 00:00 [accepted]
PHST- 2019/07/21 06:00 [entrez]
PHST- 2019/07/22 06:00 [pubmed]
PHST- 2020/01/17 06:00 [medline]
PHST- 2019/07/19 00:00 [pmc-release]
AID - 10.1186/s12931-019-1131-x [pii]
AID - 1131 [pii]
AID - 10.1186/s12931-019-1131-x [doi]
PST - epublish
SO  - Respir Res. 2019 Jul 19;20(1):162. doi: 10.1186/s12931-019-1131-x.